Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Goldman Sachs raises Eli Lilly (LLY) 2030 GLP-1 medications forecast to $130bn
May 30, 2024 11:46 AM EDTAnalysts at Goldman Sachs lifted their forecast for Eli Lilly & Co.'s (NYSE: LLY) total worldwide sales of next-generation, primarily GLP-1 receptor agonist anti-obesity medications to $130 billion in 2030 in a note Thursday.
This is up from the investment bank's prior forecast of $100... More
